<DOC>
	<DOCNO>NCT01962207</DOCNO>
	<brief_summary>The purpose study evaluate long-term antibody persistence 6 , 7 , 8 , 9 10 year receive primary vaccination meningococcal conjugate vaccine MenACWY-TT versus Meningitec™ Mencevax™ ACWY , safety immunogenicity booster dose MenACWY-TT administer 10 year primary vaccination . All subject receive primary vaccination 1 10 year age study 108658 ( NCT00427908 ) . No new subject enrol booster study .</brief_summary>
	<brief_title>To Evaluate Antibody Persistence 6 , 7 , 8 , 9 10 Years After Administration GlaxoSmithKline ( GSK ) Biologicals ' MenACWY-TT Vaccine ( GSK134612 ) Versus Meningitec Mencevax ACWY Well Safety Immunogenicity Booster Dose MenACWY-TT Vaccine 10 Years Post Primary Vaccination</brief_title>
	<detailed_description>The study aim evaluate antibody persistence post primary vaccination active control , safety immunogenicity booster dose uncontrolled post primary vaccination different phase : Persistence phase : Long-term persistence 6 , 7 , 8 , 9 10 year primary vaccination MenACWY-TT Meningitec Mencevax ACWY , study MenACWY-TT-027 . Booster phase : One month post booster vaccination MenACWY-TT vaccine ten year primary vaccination . The subject study allocate group vaccination study MenACWY-TT-027 ( NCT00427908 ) .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Subjects and/or subject ' parent ( ) /Legally Acceptable Representative ( ) ( LARs ) , opinion investigator , comply requirement protocol . A male female receive primary vaccination MenACWYTT , Meningitec Mencevax ACWY vaccine study MenACWYTT027 ( NCT00427908 ) . In alignment local law regulation , write informed consent obtain parents/LAR ( ) subject write informed assent obtain subject subject le 15 year age , write informed consent obtain subject subject achieve 15th birthday . The subject ≥15 year age time enrollment sign inform consent form , even parent/ LAR previously sign ICF subject reach legal age consent . Healthy subject establish medical history historydirected physical examination enter study . All subject must satisfy follow additional criterion prior entry booster phase : Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy ovariectomy . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Previous vaccination meningococcal polysaccharide conjugate vaccine outside study MenACWYTT027 . Note : Subjects revaccinated monovalent MenC conjugate vaccine suboptimal response persistence phase MenACWYTT027 study ( i.e . MenACWYTT028 , 029 , 030 , 031 032 ) allow participate follow persistence MenA , MenW135 MenY . History meningococcal disease due serogroup A , C , W135 Y . Previous vaccination meningococcal B vaccine . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include Human Immunodeficiency Virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . History chronic alcohol consumption and/or drug abuse . Subjects withdrew consent contact followup study . Additional exclusion criterion booster phase Month 126 study entry ( checked Month 126 ) subject : Use investigational nonregistered product study vaccine within 30 day precede booster dose study vaccine , plan use followup period . Administration vaccine foreseen study protocol period start 30 day booster dose study vaccine plan administration within 30 day vaccination , exception license inactivated influenza vaccine . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product within three month precede booster vaccination plan administration followup period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . History reaction hypersensitivity likely exacerbate component vaccine . History neurological disorder seizure , include GuillainBarré syndrome ( GBS ) . History simple , single febrile seizure permit . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C oral , axillary , tympanic , ≥38.0°C rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>10 year Meningitec</keyword>
	<keyword>Safety</keyword>
	<keyword>booster response</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Adults</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Mencevax ACWY</keyword>
</DOC>